Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Elisa Giommoni"'
Autor:
Guido Giordano, Michele Milella, Matteo Landriscina, Francesca Bergamo, Giuseppe Tirino, Antonio Santaniello, Alberto Zaniboni, Enrico Vasile, Ferdinando De Vita, Giovanni Lo Re, Vanja Vaccaro, Elisa Giommoni, Donato Natale, Raffaele Conca, Daniele Santini, Luigi Maiorino, Gianni Sanna, Vincenzo Ricci, Aldo Iop, Vincenzo Montesarchio, Letizia Procaccio, Silvia Noventa, Roberto Bianco, Antonio Febbraro, Sara Lonardi, Giampaolo Tortora, Isabella Sperduti, Davide Melisi
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Background Pancreatic cancer (PC) first‐line therapy often consists of polychemotherapy regimens, but choosing a second‐line therapy after disease progression, especially following first‐line FOLFIRINOX, remains a clinical challenge. T
Externí odkaz:
https://doaj.org/article/cf916ab2ef1c4b38b23365ff3e0dccbd
Autor:
Letizia Procaccio, Valeria Merz, Morena Fasano, Vanja Vaccaro, Elisa Giommoni, Andrea Pretta, Silvia Noventa, Maria Antonietta Satolli, Guido Giordano, Clizia Zichi, Carmine Pinto, Camilla Zecchetto, Giulia Barsotti, Ferdinando De Vita, Michele Milella, Lorenzo Antonuzzo, Mario Scartozzi, Alberto Zaniboni, Rosella Spadi, Simona Casalino, Francesca Bergamo, Chiara De Toni, Davide Melisi, Sara Lonardi
Publikováno v:
Cancer Medicine, Vol 12, Iss 13, Pp 14337-14345 (2023)
Abstract Background The NAPOLI‐I trial showed better outcome of nanoliposomal irinotecan (nal‐IRI) plus 5‐fluorouracil/leucovorin (5‐FU/LV) compared to 5‐FU/LV in patients with advanced pancreatic ductal adenocarcinoma cancer (advPDAC) prog
Externí odkaz:
https://doaj.org/article/2ba909e629d843ce87c0d79ae0e1a3c6
Autor:
Elisa Giommoni, Daniele Lavacchi, Giuseppe Tirino, Lorenzo Fornaro, Francesco Iachetta, Carmelo Pozzo, Maria Antonietta Satolli, Andrea Spallanzani, Marco Puzzoni, Silvia Stragliotto, Michele Sisani, Vincenzo Formica, Filippo Giovanardi, Antonia Strippoli, Michele Prisciandaro, Samantha Di Donato, Luca Pompella, Irene Pecora, Alessandra Romagnani, Sara Fancelli, Marco Brugia, Serena Pillozzi, Ferdinando De Vita, Lorenzo Antonuzzo
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background Perioperative FLOT (5-fluorouracil, oxaliplatin and docetaxel) has recently become the gold standard treatment for fit patients with operable gastric (GC) or gastroesophageal (GEJ) adenocarcinoma, getting a 5-year overall survival
Externí odkaz:
https://doaj.org/article/4e1e9985336f400fb0fee581324d30e7
Autor:
Elisa Giommoni, Roberta Giorgione, Agnese Paderi, Elisa Pellegrini, Elisabetta Gambale, Andrea Marini, Andrea Antonuzzo, Riccardo Marconcini, Giandomenico Roviello, Marco Matucci-Cerinic, David Capaccioli, Serena Pillozzi, Lorenzo Antonuzzo
Publikováno v:
Immuno, Vol 1, Iss 3, Pp 253-263 (2021)
Background: To date, no biomarkers are effective in predicting the risk of developing immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs). This study aims to evaluate the association between basal absolu
Externí odkaz:
https://doaj.org/article/89ab038850ba456ea03a27074856e638
Autor:
Elisa Giommoni, Evaristo Maiello, Vanja Vaccaro, Ermanno Rondini, Caterina Vivaldi, Giampaolo Tortora, Laura Toppo, Guido Giordano, Tiziana Pia Latiano, Cinzia Lamperini, Serena Pillozzi, Luca Boni, Lorenzo Antonuzzo, Francesco Di Costanzo
Publikováno v:
Current Oncology, Vol 28, Iss 3, Pp 1761-1772 (2021)
Background: Relevant improvement in first-line treatment of metastatic pancreatic cancer (mPC) was provided by FOLFIRINOX and by gemcitabine (gem) plus nab-paclitaxel (Nab-p) regimens. Regardless of the first-line treatment survival benefit, most pat
Externí odkaz:
https://doaj.org/article/af7cf3f9c61f4f568a09f101f8505b66
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Externí odkaz:
https://doaj.org/article/fcfdaf895aa34d20811909ed2969fa70
Autor:
Enrico Caliman, Sara Fancelli, Carlotta Ottanelli, Francesca Mazzoni, Luca Paglialunga, Daniele Lavacchi, Marta Rita Gatta Michelet, Elisa Giommoni, Brunella Napolitano, Federico Scolari, Luca Voltolini, Camilla Eva Comin, Serena Pillozzi, Lorenzo Antonuzzo
Publikováno v:
Cancer Treatment and Research Communications, Vol 32, Iss , Pp 100603- (2022)
Objectives: Immune checkpoint inhibitors (ICIs) have led to a paradigm shift in non-small cell lung cancer (NSCLC) treatment. We investigated absolute eosinophil count (AEC) as a predictor of clinical outcomes and toxicity in NSCLC patients receiving
Externí odkaz:
https://doaj.org/article/3cf480d4b5104565bd9fc6d9c01b622d
Autor:
Agnese Paderi, Elisabetta Gambale, Cristina Botteri, Roberta Giorgione, Daniele Lavacchi, Marco Brugia, Francesca Mazzoni, Elisa Giommoni, Susanna Bormioli, Amedeo Amedei, Serena Pillozzi, Marco Matucci Cerinic, Lorenzo Antonuzzo
Publikováno v:
Molecules, Vol 26, Iss 19, p 5789 (2021)
Background: Immune-related adverse events (irAEs) are inflammatory side effects, which can occur during immune-checkpoint(s) inhibitors (ICIs) therapy. Steroids are the first-line agents to manage irAEs because of their immunosuppressive properties.
Externí odkaz:
https://doaj.org/article/906a6d089ec74a23a9c8288953790419
Autor:
Daniele Santini, Francesco Pantano, Ferdinando Riccardi, Giovan Giuseppe Di Costanzo, Raffaele Addeo, Francesco Maria Guida, Mariella Spalato Ceruso, Sandro Barni, Paola Bertocchi, Sara Marinelli, Paolo Marchetti, Antonio Russo, Mario Scartozzi, Luca Faloppi, Matteo Santoni, Stefano Cascinu, Evaristo Maiello, Franco Silvestris, Marco Tucci, Toni Ibrahim, Gianluca Masi, Antonio Gnoni, Alessandro Comandone, Nicola Fazio, Alessandro Conti, Ilaria Imarisio, Salvatore Pisconti, Elisa Giommoni, Saverio Cinieri, Vincenzo Catalano, Vincenzo Ostilio Palmieri, Giovanni Infante, Michele Aieta, Antonio Trogu, Cosmo Damiano Gadaleta, Anna Elisabetta Brunetti, Vito Lorusso, Nicola Silvestris
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e105268 (2014)
BackgroundBone is an uncommon site of metastasis in patients with advanced hepatocellular carcinoma (HCC). Therefore, there are few studies concerning the natural history of bone metastasis in patients with HCC.Patients and methodsData on clinicopath
Externí odkaz:
https://doaj.org/article/22b1351a79dc44dc810a7ab49dc4f62f
Autor:
Nicola Silvestris, Francesco Pantano, Toni Ibrahim, Teresa Gamucci, Fernando De Vita, Teresa Di Palma, Paolo Pedrazzoli, Sandro Barni, Antonio Bernardo, Antonio Febbraro, Maria Antonietta Satolli, Paola Bertocchi, Vincenzo Catalano, Elisa Giommoni, Alessandro Comandone, Evaristo Maiello, Ferdinando Riccardi, Raimondo Ferrara, Antonio Trogu, Rossana Berardi, Silvana Leo, Alessandro Bertolini, Francesco Angelini, Saverio Cinieri, Antonio Russo, Salvatore Pisconti, Anna Elisabetta Brunetti, Amalia Azzariti, Daniele Santini
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e74402 (2013)
BackgroundBone metastasis represents an increasing clinical problem in advanced gastric cancer (GC) as disease-related survival improves. In literature, few data on the natural history of bone disease in GC are available.Patients and methodsData on c
Externí odkaz:
https://doaj.org/article/ba465d2c21ca4ee5b7057c23eeaeff1e